arrow
K

Kazumi Nishino

Osaka International Cancer Institute
H指数:35
被引数:4,190

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Plain language summary of the J-TAIL-2 study results: a study of Japanese patients with extensive-stage small cell lung cancer that followed their treatment with atezolizumab plus chemotherapy over time

J-TAIL-2研究结果的简明摘要:一项关于日本广泛期小细胞肺癌患者接受阿替利珠单抗联合化疗长期随访的研究

2026-10-010
OA
Tarlatamab in small cell lung cancer following platinum-based chemotherapy: subgroup analysis of Japanese patients from the DeLLphi-304 study

塔拉他马布在铂类化疗后的小细胞肺癌中的应用:DeLLphi-304研究中日本患者的亚组分析

2026-09-190
OAAI
Impact of preexisting interstitial lung disease on pneumonitis and survival during first-line immune checkpoint inhibitor-based therapy in non-small cell lung cancer

非小细胞肺癌患者接受一线免疫检查点抑制剂治疗期间,预存间质性肺病对肺炎及生存的影响

2026-06-210
OA
Osimertinib plus selumetinib in patients with EGFR-mutated advanced NSCLC with BRAF alterations post-progression on first-line osimertinib: ORCHARD

奥希替尼联合塞尔鲁替尼在既往一线奥希替尼进展后EGFR突变型晚期NSCLC伴BRAF突变患者中的疗效:ORCHARD研究

2026-05-180
PRE
Comparison of long-term survival between nivolumab plus ipilimumab with chemotherapy and pembrolizumab with chemotherapy in advanced non-small cell lung cancer: A multicenter retrospective cohort study

比较纳武利尤单抗联合伊匹木单抗与化疗以及帕博利珠单抗联合化疗在晚期非小细胞肺癌中的长期生存:一项多中心回顾性队列研究

2026-02-190
OAAI
Long-term follow-up results from the GLORY study: phase II study of gumarontinib in East Asian patients with MET exon 14 skipping mutated non-small cell lung cancer

GLORY研究长期随访结果:gumarontinib在MET外显子14跳跃突变的东亚非小细胞肺癌患者中的II期研究

2025-09-300
PRE
Mutation testing, treatment patterns, and outcomes in patients with unresectable stage III EGFR-mutated non-small cell lung cancer treated with chemoradiotherapy: Final analysis of a global real–world study

不可切除的III期EGFR突变非小细胞肺癌患者接受放化疗的突变检测、治疗模式与结局:一项全球真实世界研究的最终分析

2025-09-080
PREAI
RELAY: safety and efficacy of ramucirumab plus erlotinib in elderly Japanese patients with metastatic EGFR-mutated NSCLC

RELAY研究:雷莫芦单抗联合厄洛替尼在老年日本患者中针对转移性EGFR突变非小细胞肺癌的安全性与有效性

2025-09-010
PRE
J-TAIL-2: A Prospective, Observational Study of Atezolizumab Combined With Carboplatin and Etoposide in Patients With Extensive-Stage SCLC in Japan
2025-03-010
OA
Final Survival Outcomes With Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated EGFR-Mutated Metastatic NSCLC: RELAY Japanese Subset

拉姆昔利单抗联合厄洛替尼对比安慰剂联合厄洛替尼,用于未治EGFR突变型转移性非小细胞肺癌患者的最终生存结局:RELAY日本亚组

2025-02-010
OAAI
Treatment (Tx) patterns and clinical outcomes in unresectable (UR) stg III EGFR-mutation positive (EGFRm) NSCLC treated with chemoradiotherapy (CRT): Final analysis of a global real-world (rw) study

不可切除(UR)的III期EGFR突变阳性(EGFRm)非小细胞肺癌(NSCLC)接受化疗放疗(CRT)的治疗模式(Tx)和临床结局:一项全球真实世界(rw)研究的最终分析

2024-12-010
PRE
RELAY: Final Overall Survival for Erlotinib Plus Ramucirumab or Placebo in Untreated, EGFR-Mutated Metastatic NSCLC

RELAY研究:厄洛替尼联合ramucirumab或安慰剂在未治疗、EGFR突变型转移性NSCLC中的最终总生存期

2024-11-015
PRE
Final Analysis Data and Exploratory Biomarker Analysis of a Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib Monotherapy for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: The WJOG9717L Study
2024-11-011
OA
Real-World Outcomes of Subsequent Chemotherapy after Progression Following Chemoradiation and Consolidative Durvalumab Therapy in Locally Advanced Non-small Cell Lung Cancer: An Exploratory Analysis from the CRIMSON Study (HOPE-005)

局部晚期非小细胞肺癌放化疗和巩固Durvalumab治疗后进展后后续化疗的真实世界结果: 来自CRIMSON研究的探索性分析 (HOPE-005)

2024-11-012
PRE